A
Abbott India Ltd
Pharmaceuticals
₹ 35,195.00 +485.00 (1.40%)
₹ 35,195.00 +485.00 (1.40%)
- NSE
- BSE
Overview
- BSE Code 500488
- NSE Symbol ABBOTINDIA
- ISIN Demat INE358A01014
- Book Value (₹) 1,992.07
- Face Value (₹) 10.00
- Market Cap (₹ Cr.) 72,566.31
- P/E (TTM) 51.30
- EPS (TTM) 665.62
- Div Yield (%) 1.39
Performance
Today’s Low 34,215.00
Today’s High 35,310.00
52W Low 25,325.00
52W High 37,000.00
Open 34,600.00
Prev. Close 34,710.00
Volume 14,011.00
Corporate Actions
No Data Found
About Abbott India Ltd
History
Abbott India Ltd. is one of the leading multinational pharmaceutical companies in India. It operates with an owned manufacturing facility in Goa and various independent contract/third-party manufacturers based across the country. Abbott India Ltd was originally incorporated on August 22, 1944, as Boots Pure Drug Company (India) Ltd. On July 1, 2002, they got their present name, Abbott India Ltd. In the year 2004, the company started the production of capsules and nutritional products. During the financial year ended March 31, 2016, Abbott India launched 17 new products in various therapy segments, which together contributed 1.9% of the net sales of the company. In the same year, the company made a strategic entry into into a licensing arrangement with Bharat Biotech India Limited to market vaccines in the immunology segment. During FY 2019, the company executed 25 new studies and published 45 articles in major indexed journals, with 6 international presentations. During the year 2022, the company continued portfolio expansion and launched 10 new differentiated products in the market to meet increasing healthcare needs. It increased presence in high-growth therapy areas such as adult vaccination and new sub-therapies like menopause.Business Segments
Abbott India supplies products and solutions across various therapeutic areas such as Women's Health, Gastroenterology, Central Nervous System, Metabolics, Multi-Specialty, Vaccines, Consumer Health, etc. Its global products include Brufen, Prothiaden, Thyronorm and Leptos. The company has four divisions:- The Primary Care division markets products in the areas of pain management and gastroenterology.
- The Specialty Care-Methabolics and Urology division offers solutions in the areas of thyroid, obesity, diabetes and benign prostatic hyperplasia.
- The Specialty Care-Neuroscience division has a varied portfolio with specialty products in neurology and psychiatric segments.
- Hospital Care delivers products in the field of anesthesiology and neonatology, such as Forane, Sevorane and Survanta.
Subsidiaries
The company does not have any subsidiaries as of March 31, 2023.Key Personnel
Mr. Munir Shaikh, Chairman Mr. Sheikh joined Abbott in 1968 and has served in several management positions with Abbott Asia, Latin America and the United States, including as General Manager in Pakistan, as Director of Business Development, Regional Director of Pacific / Asia / Africa, etc. Mr. Vivek V Kamath, Managing Director Mr. Kamath has over 30 years of rich and diversified experience in healthcare, including pharmaceuticals, OTC and diagnostics. Prior to joining the Company, Mr Kamath worked as the General Manager of the Specialty Care business of Abbott Healthcare Private Limited. Prior to Abbott, he worked with MSD Pharmaceuticals; Roche Diagnostics, India; Novartis, Singapore; Ranbaxy; Pfizer, India; Fulford, India; Wockhardt and Johnson & Johnson.Corporate Actions
The company has not performed any rights issue, bonus issue, stock split or buyback in recent years. Mergers and Acquisitions- In 2010, the organization’s board of directors approved the draft scheme for the amalgamation of Solvay Pharma India into Abbott India.
- In the year 2003, the organization's wholly-owned subsidiary organization, Lenbrook Pharmaceuticals Ltd, was amalgamated with the organization.
Financial Performance
- The organization has increased its sales by 30.68% from ₹4,093 crore in FY 2020 to ₹5,349 crore in FY 2023.
- In the same period, its operating profit margin increased from 18% to 23%.
- In the aforementioned period, its positive cash flow has also increased from ₹8 crore to ₹107 crore.
| Founded | : 1944 |
| Chairman | : Munir Shaikh |
| Managing Director | : SWATI ROHAN DALAL |
| Address | : Unit No 3 Corporate Park, Sion Trombay Road Chembur, Mumbai, Maharashtra, 400071, |
| HO Tel | : 91-022-3816 2000 |
Open A Free Demat Account Today
Get StartedDocuments To Be Kept Handy
- PAN Card
- Cancelled Cheque
- Latest 6 month Bank Statement (Only for Derivatives Trading)